Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People's Republic of China.
Department of Orthopaedic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People's Republic of China.
Int J Nanomedicine. 2019 Apr 8;14:2451-2464. doi: 10.2147/IJN.S197541. eCollection 2019.
Acute myocardial infarction (AMI), usually caused by atherosclerosis of coronary artery, is the most severe manifestation of coronary artery disease which results in a large amount of death annually. A new diagnosis approach with high accuracy, reliability and low measuring-time-consuming is essential for AMI quick diagnosis.
The objective of this study was to develop a new point-of-care testing system with high accuracy and reliability for AMI quick diagnosis.
50 plasma samples of acute myocardial infarction patients were analyzed by developed Smartphone-Assisted Pressure-Measuring-Based Diagnosis System (SPDS). The concentration of substrate was firstly optimized. The effect of antibody labeling and matrix solution on measuring result were then evaluated. And standard curves for cTnI, CK-MB and Myo were built for clinical sample analysis. The measuring results of 50 clinical samples were finally evaluated by comparing with the measuring result obtained by CLIA.
The concentration of substrate HO was firstly optimized as 30% to increase measuring signal. A commercial serum matrix was chosen as the matrix solution to dilute biomarkers for standard curve building to minimize matrix effect on the accuracy of clinical plasma sample measuring. The standard curves for cTnI, CK-MB and Myo were built, with measuring dynamic range of 0-25 ng/mL, 0-33 ng/mL and 0-250 ng/mL, and limit of detection of 0.014 ng/mL, 0.16 ng/mL and 0.85 ng/mL respectively. The measuring results obtained by the developed system of 50 clinical plasma samples for three biomarkers matched well with the results obtained by chemiluminescent immunoassay.
Due to its small device size, high sensitivity and accuracy, SPDS showed a bright potential for point-of-care testing (POCT) applications.
急性心肌梗死（AMI）通常由冠状动脉粥样硬化引起，是导致每年大量死亡的最严重的冠状动脉疾病表现。对于 AMI 的快速诊断，需要一种具有高精度、高可靠性和低测量耗时的新诊断方法。
本研究旨在开发一种具有高精度和可靠性的即时护理检测系统，用于 AMI 的快速诊断。
使用开发的智能手机辅助压力测量诊断系统（SPDS）分析了 50 份急性心肌梗死患者的血浆样本。首先优化了底物浓度。然后评估了抗体标记和基质溶液对测量结果的影响，并为临床样本分析建立了 cTnI、CK-MB 和 Myo 的标准曲线。最后通过与 CLIA 获得的测量结果进行比较，评估了 50 份临床样本的测量结果。
首先将底物 HO 的浓度优化为 30%，以增加测量信号。选择商业血清基质作为稀释生物标志物的基质溶液，以最小化基质效应对临床血浆样本测量准确性的影响。建立了 cTnI、CK-MB 和 Myo 的标准曲线，测量动态范围分别为 0-25ng/mL、0-33ng/mL 和 0-250ng/mL，检测限分别为 0.014ng/mL、0.16ng/mL 和 0.85ng/mL。该系统对 50 份临床血浆样本中三种生物标志物的测量结果与化学发光免疫测定法的结果吻合良好。
由于其设备体积小、灵敏度和准确性高，SPDS 在即时护理检测（POCT）应用中具有广阔的应用前景。
